Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.

NCT03236974 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Postmenopausal Women With ER+ HER2- Primary Breast Cancer

Interventions

DRUG: Standard Arm - Fulvestrant
DRUG: AZD9496

Sponsor

AstraZeneca